Medical Education podcast by COR2ED. Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics discussed at ASCO GI 2022 and EASL liver cancer summit 2022 in hepatocellular carcinoma. He discusses the HIMALAYA study which evaluated dual immune checkpoint blockade inhibition namely, anti-CTLA-4 antibody tremelimumab with the anti-PD-L1 antibody durvalumab in the frontline setting with patients with unresectable hepatocellular carcinoma. There were other important studies at the meeting and Prof Harding highlights the RENOBATE study and the GOING study that evaluated nivolumab in combination with regorafenib and early addition of nivolumab to regorafenib regimen, respectively.
Prof. Thomas Powles, a Medical Oncologist from Barts Cancer Centre in the UK and Dr Friederike Schlürmann a Medical Oncologist from University Hospital of...
COR2ED Medical Education: In this podcast episode, Prof. Kris Kowdley, Director, Liver Institute Northwest, Washington State University, USA and Prof. Jörn Schattenberg, Director, Metabolic...
COR2ED Medical Education: This episode, covers the highlights on colorectal cancer from ASCO GI 2023. Prof. Andrea Sartore-Bianchi (Niguada Cancer Center, Milan, Italy) and...